NRx Pharmaceuticals, Inc.

NASDAQ:NRXP

Biotechnology

Healthcare
$2.55 +1.43%

+$0.06 today

Market cap
$113.04M
Beta
2.19
P/E (TTM)
-5.3
EPS (TTM)
-$0.76
52W Low $1.62High $5.06

Volume 1.39M

Average 1.27M

Returns on capital

NRx Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

179.6%

avg -35.5%

ROIC

106.0%

avg 72.4%

ROA

-220.9%

avg -391.0%

Analysis

ROE is currently the strongest return metric at 179.6% versus its period average of -35.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jonathan C. Javitt

Co-Founder, Chairman & CEOUSD 846.77K69150.00K0.87%

Michael S. Abrams

CFO & TreasurerUSD 363.08K5675.00K0.43%

Riccardo Panicucci

Chief Manufacturing & Technology OfficerUSD 240K64——

Dennis K. McBride

Chief Strategy Officer & DirectorUSD 38.46K71——

Hervé Perron

Chief Scientist—67——

Philip T. Lavin

Chief Methodologist—79——

Glenn Tyson

Chief Commercial Officer————

Joseph Casper

Chief Operating Officer—75——

Michael Taylor

Chief Development Officer & Director—51——

Joshua C. Brown

Chief Medical Innovation Officer————

Suzanne Messere

Investor Relations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 28, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
+278.2% (5yr)1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Forward estimates point to Revenue at +278.2% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does NRx Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about NRXP's management, answered from reported figures.

Who manages NRXP?

NRx Pharmaceuticals, Inc. (NRXP) lists 11 active executives. The top listed executive is Dennis K. McBride, Chief Strategy Officer & Director.

Are NRXP insiders buying or selling?

Recent insider activity shows net buying of $20.54M.